A phase 3 clinical trial recently revealed that when previously untreated multiple myeloma (MM) patients ineligible for transplant received a standard combination of lenalidomide and dexamethasone, daratumumab significantly extends progression-free survival (PFS). A lead investigator—Thierry Facon, MD, professor of hematology at the Lille University School of Medicine, France—reports that “on the basis of these results, we believe that daratumumab should be considered the new standard of care for this patient group.”

Follow the link to Clinical Oncology below for more details from this important study.

Source: Clinical Oncology

Pin It on Pinterest